{"id":687912,"date":"2022-09-22T07:04:26","date_gmt":"2022-09-22T11:04:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/"},"modified":"2022-09-22T07:04:26","modified_gmt":"2022-09-22T11:04:26","slug":"decibel-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/","title":{"rendered":"Decibel Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BOSTON, Sept.  22, 2022  (GLOBE NEWSWIRE) &#8212; Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022, at 10:00 a.m. ET in New York, NY.<\/p>\n<p>A live webcast of the fireside chat may be accessed by visiting the Investors section of the Decibel Therapeutics website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Bs7eDxuXcMp1dpy3YRUhDrcVZ_hECIIYlDNx03tM9eBaBesFBLnD3kWaz83Y8rr3wZvqJE__RDpGTK3q_WRwXODppHRbX3VEZ9holrM4_HY=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/ir.decibeltx.com<\/a>. An archived replay of the webcast will be available on the Company\u2019s website for approximately 90 days following the fireside chat. <\/p>\n<p><strong>About Decibel Therapeutics<\/strong><\/p>\n<p>Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel\u2019s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all. For more information about Decibel Therapeutics, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3ZYwQ93zy8wNmPqI1BpJCUK11Aj5YDDevm4TtpGM5-_Y6cI05dz6NDuk0ZtRiTJZlJm-koMOPCnrRYXn34j6Lhi4tX8_7nM74gtLAKmYmfk=\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.decibeltx.com<\/u><\/a> or follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CyV0xg65RAixhwSmaUa8rm8hEEvukee6pzx_WnuXM3bZSg4YzNRsCWlYKa3NAPHVUG_bavTTzmYXCIbsT3d4XA==\" rel=\"nofollow noopener\" target=\"_blank\"><u>Twitter<\/u><\/a>.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Julie Seidel<br \/>Stern Investor Relations, Inc.<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0m-a5gMVAli1NtCBwpi3Zbj38BNyc1tuvJIOfA06QC7LKPn9ekYIlWsfmwlpqFV4Je0_FeEOe_R5NLyrhNlzAc4PCw1u0QvPOBto1O4vFos=\" rel=\"nofollow noopener\" target=\"_blank\">julie.seidel@sternir.com<\/a><\/u><br \/>212-362-1200<\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Chris Railey<br \/>Ten Bridge Communications<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=__gvYgMr6afbEdtsBpERsPZY2lpE7T-x1DXoIBMjlw48nXengp5MhuyXl3FytN-178X7PKJScRlT_zrjwfv8Qwp3FCKY0hgl7U--EpLZWNX4v0HDc_RVms83r7TKLljM\" rel=\"nofollow noopener\" target=\"_blank\">Chris@tenbridgecommunications.com<\/a><\/u><br \/>617-834-0936<\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDk4MiM1MTY1MTA4IzIyMDU3NTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NDQ0NjlkNjAtNTM1NS00MjgwLWI5ODAtMjJmYTY1YTQzN2EyLTEyMTczMDY=\/tiny\/Decibel-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) &#8212; Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022, at 10:00 a.m. ET in New York, NY. A live webcast of the fireside chat may be accessed by visiting the Investors section of the Decibel Therapeutics website at https:\/\/ir.decibeltx.com. An archived replay of the webcast will be available on the Company\u2019s website for approximately 90 days following the fireside chat. About Decibel Therapeutics Decibel Therapeutics is a clinical-stage biotechnology company dedicated to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Decibel Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-687912","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Decibel Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Decibel Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) &#8212; Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022, at 10:00 a.m. ET in New York, NY. A live webcast of the fireside chat may be accessed by visiting the Investors section of the Decibel Therapeutics website at https:\/\/ir.decibeltx.com. An archived replay of the webcast will be available on the Company\u2019s website for approximately 90 days following the fireside chat. About Decibel Therapeutics Decibel Therapeutics is a clinical-stage biotechnology company dedicated to &hellip; Continue reading &quot;Decibel Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-22T11:04:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDk4MiM1MTY1MTA4IzIyMDU3NTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Decibel Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit\",\"datePublished\":\"2022-09-22T11:04:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\\\/\"},\"wordCount\":293,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MDk4MiM1MTY1MTA4IzIyMDU3NTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\\\/\",\"name\":\"Decibel Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MDk4MiM1MTY1MTA4IzIyMDU3NTM=\",\"datePublished\":\"2022-09-22T11:04:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MDk4MiM1MTY1MTA4IzIyMDU3NTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MDk4MiM1MTY1MTA4IzIyMDU3NTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/decibel-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Decibel Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Decibel Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/","og_locale":"en_US","og_type":"article","og_title":"Decibel Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit - Market Newsdesk","og_description":"BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) &#8212; Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022, at 10:00 a.m. ET in New York, NY. A live webcast of the fireside chat may be accessed by visiting the Investors section of the Decibel Therapeutics website at https:\/\/ir.decibeltx.com. An archived replay of the webcast will be available on the Company\u2019s website for approximately 90 days following the fireside chat. About Decibel Therapeutics Decibel Therapeutics is a clinical-stage biotechnology company dedicated to &hellip; Continue reading \"Decibel Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-22T11:04:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDk4MiM1MTY1MTA4IzIyMDU3NTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Decibel Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit","datePublished":"2022-09-22T11:04:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/"},"wordCount":293,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDk4MiM1MTY1MTA4IzIyMDU3NTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/","name":"Decibel Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDk4MiM1MTY1MTA4IzIyMDU3NTM=","datePublished":"2022-09-22T11:04:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDk4MiM1MTY1MTA4IzIyMDU3NTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDk4MiM1MTY1MTA4IzIyMDU3NTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/decibel-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Decibel Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/687912","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=687912"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/687912\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=687912"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=687912"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=687912"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}